Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Designs “Arogya Parivar” To Reach Real India In Its Rural Centers

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Swiss drug maker Novartis recently launched its ace anti-diabetes drug Galvus in India to take Merck's Januvia head on, but the company's larger focus seems to be shifting fast from the mega cities to the rural market where "real India lives.

You may also be interested in...



Green Shoots Of Health Care Delivery In India’s Neglected Northeast

India’s northeast combines a rural population that lacks access to basic health care in many cases in terrain dissected by rivers, jungles and mountains. The World Bank has identified funding several models of sustainable and scalable health care delivery for start-ups that transcend such barriers.

Novartis Stays Firm On India Plans After Gleevec: An Interview With India Vice Chairman Ranjit Shahani

Novartis has been at the center of a long patent controversy, and although it recently faced an adverse ruling, India Vice Chairman Ranjit Shahani’s optimism about the Indian market is unshaken.

Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India

MUMBAI - For many years Swiss pharmaceutical giant Novartis voiced reservations about certain provisions of the Indian patent laws and data exclusivity issues, but the maker of Glivec (imatinib) looks set to introduce its next-line therapy for chronic myeloid leukemia Tasigna (nilotinib) into the Indian market

Related Content

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel